Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin glargine versus liraglutide in insulin-naive adults with inadequately controlled type 2 diabetes
2010-018437-21Phase 4Completed
- Sponsor
- Sanofi
- Start
- Apr 2010
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of insulin glargine and liraglutide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Sanofi. Primary endpoint: Percentage of patients reaching HbA1c < 7% at the end of the comparative period. Started Apr 2010; status: completed.
02
Drugs
insulin glargineliraglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2010-018437-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018437-21.